Aji­nomo­to to buy gene ther­a­py CD­MO Forge Bi­o­log­ics in $620M all-cash deal

CD­MO and biotech Forge Bi­o­log­ics will be ac­quired by Aji­nomo­to in an all-cash deal worth $620 mil­lion, a move that will see the Japan-based multi­na­tion­al con­glom­er­ate en­ter the gene ther­a­py man­u­fac­tur­ing space.

“Clear­ly, Aji­nomo­to is see­ing this as a bet on the fu­ture of gene ther­a­py, and that this will be­come a more im­por­tant part of CD­MO of­fer­ings in­to the fu­ture,” Forge board chair Chris Garabe­di­an told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER